AIM ImmunoTech (NYSEAMERICAN:AIM) Issues Earnings Results

Posted by Linda Flegge on Nov 19th, 2025

AIM ImmunoTech (NYSEAMERICAN:AIM – Get Free Report) released its quarterly earnings results on Monday. The company reported ($1.57) EPS for the quarter, FiscalAI reports. AIM ImmunoTech had a negative net margin of 13,360.33% and a negative return on equity of 1,586.23%. The business had revenue of $0.03 million during the quarter.

AIM ImmunoTech Stock Down 7.6%

Shares of NYSEAMERICAN AIM opened at $1.33 on Wednesday. AIM ImmunoTech has a 52 week low of $1.31 and a 52 week high of $36.00. The business’s 50 day moving average price is $2.36 and its 200 day moving average price is $5.33. The firm has a market cap of $3.60 million, a P/E ratio of -0.05 and a beta of 1.03.

Hedge Funds Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Sabby Management LLC purchased a new stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 28,855 shares of the company’s stock, valued at approximately $79,000. AIM ImmunoTech makes up 0.1% of Sabby Management LLC’s portfolio, making the stock its 22nd biggest position. Sabby Management LLC owned 1.06% of AIM ImmunoTech at the end of the most recent reporting period. 12.02% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Maxim Group raised shares of AIM ImmunoTech to a “strong-buy” rating in a research report on Friday, September 5th. Zacks Research upgraded shares of AIM ImmunoTech from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Strong Buy” and a consensus price target of $450.00.

View Our Latest Report on AIM

About AIM ImmunoTech

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).